Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21488593 | 0.81 | CA2 (0.34) | ALDH1A1CA2MLYCDESR1KCNH2 | |
| SCHEMBL6446520 | 0.80 | PSENEN (0.41) | ALDH1A1HPGDCA14CA2PSENEN | |
| SCHEMBL21488681 | 0.79 | ALDH1A1 (0.34) | ALDH1A1HPGDCA12CA14CA2 | |
| SCHEMBL6443429 | 0.76 | ALDH1A1 (0.42) | ALDH1A1HPGDCA2GAATSHR | |
| SCHEMBL21488437 | 0.76 | CA12 (0.36) | ALDH1A1CA12CA14MAPTHSD17B10 | |
| SCHEMBL6444677 | 0.76 | ALDH1A1 (0.42) | ALDH1A1HPGDCA2GAATSHR | |
| SCHEMBL13576867 | 0.76 | CA2 (0.37) | ALDH1A1CA2MLYCDMEN1KMT2A | |
| SCHEMBL21488489 | 0.75 | CA12 (0.35) | ALDH1A1CA12CA14MAPTHSD17B10 | |
| SCHEMBL21166799 | 0.75 | CA2 (0.36) | ALDH1A1HPGDCA2MLYCDESR1 | |
| SCHEMBL11649038 | 0.75 | CA2 (0.36) | ALDH1A1CA2MLYCDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3908571-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | XWPharma Ltd. (KY) | 2021-11-17 | — | — | EP | claimed |
| WO-2020143198-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | XW LABORATORIES INC. (KY) | 2020-07-16 | — | — | WO | claimed |
| US-20190322618-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | XWPharma Ltd. (KY) | 2019-10-24 | — | — | US | claimed |
| EP-4384145-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2024-06-19 | — | — | EP | disclosed |
| US-20230285325-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2023-09-14 | — | — | US | disclosed |
| US-11690811-B2 | Pharmaceutical compositions and oral dosage forms of ketamine derivatives | XWPharma Ltd. (KY) | 2023-07-04 | — | — | US | disclosed |
| US-20230098084-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2023-03-30 | — | — | US | disclosed |
| WO-2023018966-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2023-02-16 | — | — | WO | disclosed |
| EP-3908571-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | XWPharma Ltd. (KY) | 2021-11-17 | — | — | EP | disclosed |
| WO-2020143198-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | XW LABORATORIES INC. (KY) | 2020-07-16 | — | — | WO | disclosed |
| US-20190322618-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | XWPharma Ltd. (KY) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322618-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | OPRK1, KCNK10, KCNK17 | ALDH1A1 2003/4885HPGD 1263/4885CA12 4848/4885 |
| US-11690811-B2 | Pharmaceutical compositions and oral dosage forms of ketamine derivatives | OPRK1, KCNK5, KCNK17 | ALDH1A1 2360/4885HPGD 556/4885CA12 4117/4885 |
| US-20230098084-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | OPRK1, KCNK5, KCNK17 | ALDH1A1 2360/4885HPGD 556/4885CA12 4117/4885 |
| US-20230285325-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | OPRK1, KCNK5, KCNK17 | ALDH1A1 2360/4885HPGD 556/4885CA12 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.